FTREFortrea Holdings Inc. Common Stock

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at Fortrea (NASDAQ:FTRE) and the best and worst performers in the drug development inputs & services industry.

Well-known pharmaceutical companies such as Merck and Pfizer typically manage this complex process in house. Medpace Holdings which targets oncology, metabolic, cardiology, central nervous system, and anti-infective therapies, raised its 2026 revenue guidance on July’s second-quarter conference call to a midpoint of $2.85 billion, corresponding to a year-over-year increase of 13%. Three months later, Medpace is in the pink: On the heels of second-quarter earnings, the stock is up 14%.

Investment management company Curreen Capital released its second-quarter 2026 Investor letter. A copy of the letter can be downloaded here. In the second quarter, the fund returned 22.26% compared to 15.20% for the S&P 500 Index. The performance was driven by active special case investments, including buying a tender offer, a merger-spinoff, and investments in […]

Fortrea Holdings (FTRE) is back in focus after reporting Q2 2026 results that exceeded analyst expectations and lifting its full year 2026 revenue and EBITDA guidance, citing stronger biotech demand and tighter execution. See our latest analysis for Fortrea Holdings. At a share price of $18.43, Fortrea Holdings has a 90 day share price return of 22.95% and a 1 year total shareholder return of 180.09%. This suggests momentum has picked up recently despite earlier three year total shareholder...

In late July 2026, Fortrea Holdings Inc. raised its full-year 2026 revenue guidance to US$2.62 billion–US$2.69 billion and reported second-quarter sales of US$678.2 million alongside a sharply reduced net loss of US$13.2 million versus a year earlier. On the governance side, the board appointed director David Smith as Interim Chief Financial Officer after a court order placed recently hired CFO Jason Knoblauch on paid leave, adding an experienced pharmaceutical finance leader to oversee...

Biotech demand strengthens as backlog hits $7.8 billion and guidance rises.

ICLR's discounted valuation and $23.4B backlog support upside potential, but falling estimates, weaker margins and execution risks argue for patience.

Fortrea Holdings Inc. (FTRE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

FTRE vs. ARGX: Which Stock Is the Better Value Option?

FTRE, ASML and KLAC made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on July 31, 2026.

Fortrea Holdings Inc (FTRE) reports improved revenue guidance and sustained commercial momentum, despite facing revenue decline and leadership changes.

Fortrea (NASDAQ:FTRE) reported second-quarter 2026 revenue of $678.2 million and adjusted EBITDA of $58.7 million, while raising its full-year revenue and adjusted EBITDA outlook. Management said results reflected stronger clinical pharmacology performance, cost-savings initiatives and improving com

Fortrea Holdings Inc. (FTRE) delivered earnings and revenue surprises of +27.78% and +4.62%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Clinical research company Fortrea Holdings (NASDAQ:FTRE) reported Q2 CY2026 results exceeding the market’s revenue expectations, but sales fell by 4.5% year on year to $678.2 million. The company’s full-year revenue guidance of $2.66 billion at the midpoint came in 1.8% above analysts’ estimates. Its non-GAAP profit of $0.23 per share was 27.2% above analysts’ consensus estimates.

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be announcing earnings results this Wednesday morning. Here’s what to look for.

Fortrea trades at $17.93 and has moved in lockstep with the market. Its shares have returned 13.3% over the last six months while the S&P 500 has gained 11.4%.